UNSPSC 51263005: Zolertine

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C13H18N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EMD433OT6A, chemically known as piperazine, 1-phenyl-4-(2-(1h-tetrazol-5-yl)ethyl)- but generally known as zolertine, which bears US NIH Compound Identifier 23669. European Medicines Agency schedules Zolertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00178MIG.

UNSPSC 51263005 Zolertine (Commodity) covers pharmaceutical products and related health interventions procured by state and local agencies, though recent solicitations show state and local governments using this code to buy naloxone, safe drug deactivation systems, and to evaluate direct-to-manufacturer prescription delivery models. Seminole County, Florida recently issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county community health building and a two-year term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI to gather vendor capability data on implementing a Therapeutic Pharmacy Initiative that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, bypassing traditional pharmacy benefit managers and wholesalers. Solicitations name county health departments and state HHS agencies as issuing bodies, suggesting the code draws activity from public health and human services authorities rather than broader municipal procurement.

Seminole County, Florida and the Texas Health and Human Services Commission represent the recent geographic footprint, with the Florida opportunity requiring delivery to Sanford and the Texas RFI addressing statewide pharmacy benefit restructuring. The Seminole County IFB (IFB60459723LAS) closed July 26, 2023, requiring vendors to submit unit costs electronically, maintain E-Verify compliance, and carry workers' compensation and commercial general liability insurance; the procurement noted potential FEMA funding and a three-month probationary termination right. The Texas RFI (HHS0017013), posted April 3, 2026 with the same-day response deadline, sought vendor experience with direct contracting for self-insured employers and health plans, negotiated net pricing without rebates, and value-based agreements, though no formal award or budget values are identified at the RFI stage. The code shows limited recent activity and a narrow issuing-body profile; opportunities present here focus on access-to-addiction-treatment supplies and pharmacy benefit program restructuring rather than broader pharmaceutical procurement.